Lucid Diagnostics Net Worth
Lucid Diagnostics Net Worth Breakdown | LUCD |
Lucid Diagnostics Net Worth Analysis
Lucid Diagnostics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Lucid Diagnostics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Lucid Diagnostics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Lucid Diagnostics' net worth analysis. One common approach is to calculate Lucid Diagnostics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Lucid Diagnostics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Lucid Diagnostics' net worth. This approach calculates the present value of Lucid Diagnostics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Lucid Diagnostics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Lucid Diagnostics' net worth. This involves comparing Lucid Diagnostics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Lucid Diagnostics' net worth relative to its peers.
Enterprise Value |
|
To determine if Lucid Diagnostics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lucid Diagnostics' net worth research are outlined below:
| Lucid Diagnostics is way too risky over 90 days horizon | |
| Lucid Diagnostics may become a speculative penny stock | |
| Lucid Diagnostics appears to be risky and price may revert if volatility continues | |
| Lucid Diagnostics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.43 M. Net Loss for the year was (52.67 M) with loss before overhead, payroll, taxes, and interest of (2.22 M). | |
| Lucid Diagnostics currently holds about 34.46 M in cash with (32.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Lucid Diagnostics has a poor financial position based on the latest SEC disclosures | |
| Roughly 45.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard Esophageal DNA Test |
Lucid Diagnostics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lucid Diagnostics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lucid Diagnostics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Lucid Diagnostics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lucid Diagnostics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lucid Diagnostics backward and forwards among themselves. Lucid Diagnostics' institutional investor refers to the entity that pools money to purchase Lucid Diagnostics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Lpl Financial Corp | 2024-12-31 | 53.4 K | Geneos Wealth Management Inc | 2024-12-31 | 29.6 K | Blackrock Inc | 2024-12-31 | 27.3 K | State Street Corp | 2024-12-31 | 27 K | Americana Partners, Llc | 2024-12-31 | 26.4 K | Xtx Topco Ltd | 2024-12-31 | 25.3 K | Two Sigma Securities, Llc | 2024-12-31 | 19.3 K | Jane Street Group Llc | 2024-12-31 | 13.8 K | Northern Trust Corp | 2024-12-31 | 13.1 K | Luminus Management, Llc | 2024-12-31 | 1 M | Vanguard Group Inc | 2024-12-31 | 560.9 K |
Follow Lucid Diagnostics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 122.95 M.Market Cap |
|
Project Lucid Diagnostics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.83) | (1.93) | |
| Return On Capital Employed | 20.66 | 21.69 | |
| Return On Assets | (1.74) | (1.83) | |
| Return On Equity | 20.51 | 21.54 |
When accessing Lucid Diagnostics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Lucid Diagnostics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lucid Diagnostics' profitability and make more informed investment decisions.
Please note, the presentation of Lucid Diagnostics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lucid Diagnostics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Lucid Diagnostics' management manipulating its earnings.
Evaluate Lucid Diagnostics' management efficiency
Lucid Diagnostics has return on total asset (ROA) of (1.0102) % which means that it has lost $1.0102 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.0783) %, meaning that it created substantial loss on money invested by shareholders. Lucid Diagnostics' management efficiency ratios could be used to measure how well Lucid Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Lucid Diagnostics' Return On Equity is projected to increase significantly based on the last few years of reporting. At present, Lucid Diagnostics' Intangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.09, whereas Total Assets are forecasted to decline to about 26.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.05) | (0.05) | |
| Tangible Book Value Per Share | (0.08) | (0.08) | |
| Enterprise Value Over EBITDA | (1.28) | (1.21) | |
| Price Book Value Ratio | (22.93) | (24.08) | |
| Enterprise Value Multiple | (1.28) | (1.21) | |
| Price Fair Value | (22.93) | (24.08) | |
| Enterprise Value | 63.5 M | 60.3 M |
Lucid Diagnostics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 40.6618 | Revenue | Quarterly Revenue Growth 0.497 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lucid Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lucid Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lucid Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lucid Diagnostics time-series forecasting models is one of many Lucid Diagnostics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lucid Diagnostics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Lucid Diagnostics Earnings per Share Projection vs Actual
Lucid Diagnostics Corporate Management
| Lishan MD | Chairman CEO | Profile | |
| Joseph MD | Strategic Cofounder | Profile | |
| Deepika Lakhani | Chief Officer | Profile | |
| Michael Gordon | General Secretary | Profile | |
| Michael Parks | Vice Relations | Profile | |
| Adrian Miller | VP Relations | Profile | |
| Amitabh MD | Strategic Cofounder | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share | Quarterly Revenue Growth 0.497 | Return On Assets | Return On Equity |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.